Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.